Tikvah Management LLC purchased a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 2,460,833 shares of the company's stock, valued at approximately $8,908,000. Atyr PHARMA comprises about 2.5% of Tikvah Management LLC's investment portfolio, making the stock its 15th largest holding. Tikvah Management LLC owned about 2.93% of Atyr PHARMA as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Wells Fargo & Company MN acquired a new stake in Atyr PHARMA in the 4th quarter worth approximately $383,000. ExodusPoint Capital Management LP acquired a new stake in Atyr PHARMA in the 4th quarter valued at $61,000. Knott David M Jr purchased a new position in shares of Atyr PHARMA in the fourth quarter valued at approximately $1,115,000. Geode Capital Management LLC acquired a new stake in Atyr PHARMA during the 4th quarter worth $3,229,000. Finally, Diametric Capital LP purchased a new stake in Atyr PHARMA during the 4th quarter valued at about $108,000. 61.72% of the stock is currently owned by institutional investors.
Atyr PHARMA Stock Down 1.6 %
Shares of ATYR traded down $0.05 during trading hours on Thursday, hitting $2.83. 714,250 shares of the company were exchanged, compared to its average volume of 887,247. The firm's 50 day moving average is $3.49 and its 200-day moving average is $3.25. Atyr PHARMA INC has a 52 week low of $1.42 and a 52 week high of $4.66. The company has a market cap of $251.03 million, a PE ratio of -3.01 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, equities research analysts forecast that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ATYR. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an "overweight" rating on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Friday, March 14th. Finally, Leerink Partners initiated coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $18.60.
Read Our Latest Analysis on ATYR
About Atyr PHARMA
(
Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
